Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
深入研究阿里拉姆製藥股票：分析師觀點（6個評級）
A clear picture of Alnylam Pharmaceuticals...6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月內有6位分析師分享了對阿里拉姆製藥（納斯達克:AGIO）的評價，表達了看好和看淡觀點的混合。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天內情緒的變化，並將它們與前幾個月進行比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25.
分析師對12個月價格目標的評估提供了額外的見解，展示了53.5美元的平均目標，最高估值爲56.00美元，最低估值爲51.00美元。當前的平均值較上一個55.25美元的平均價格目標下降了3.17%。
Decoding Analyst Ratings: A Detailed Look
分析師評級解讀：詳細解析
A clear picture of Alnylam Pharmaceuticals...
通過對最近分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間